Mount Tam Biotechnologies, headquartered at the Buck Institute in Novato, has announced the appointment of Richard Marshak as CEO. He succeeds interim CEO Dr Tim Powers, who remains with the company as Chief Science Officer. Mount Tam Biotechnologies was founded on World Lupus Day 2014 to develop, optimize and bring to market treatments for autoimmune diseases, and holds an exclusive licensing and collaboration agreement with the Buck Institute for Research on Aging. Brian Kennedy, Chairman of Mount Tam and CEO of the Buck comments, “We are excited to bring Richard on board as his skills and experience are a strong complement to our core capabilities. We see this as a critical next step for Mount Tam, and we look forward to accelerating our path to success. By bringing Richard on as CEO we expect to fully leverage the substantial Mount Tam IP portfolio, its collaboration with the Buck Institute, and the exciting clinical opportunities for mTOR inhibitors.”
For more information visit the Mount Tam Biotechnologies website.